1. Phylogeny – JAK2 is a member of the Janus kinase family, which comprises four paralogous enzymes: JAK1, JAK2, JAK3, and TYK2. Orthologs of JAK2 have been identified throughout vertebrate species, and its overall domain‐structure is highly conserved across these species, indicating an ancient evolutionary origin of cytokine receptor signaling components (hubbard2018mechanisticinsightsinto pages 1-2, jatiani2010jakstatpathwaysin pages 1-2). Within the human kinome, JAK2 is assigned to a distinct group of non‐receptor tyrosine kinases that share the common architecture of a FERM domain, an SH2-like domain, a pseudokinase domain, and the active kinase domain. It is phylogenetically related to other JAK family members that evolved from a common ancestral kinase, with evolutionary studies further supporting its conservation from early eukaryotes to modern vertebrates (lindauer2001predictionofthe pages 1-2, jatiani2010jakstatpathwaysin pages 2-3).
2. Reaction Catalyzed – The catalytic reaction mediated by JAK2 follows the typical phosphorylation mechanism of protein tyrosine kinases. In the presence of ATP, JAK2 transfers the γ-phosphate from ATP to specific tyrosine residues on substrate proteins such as cytokine receptors and STAT transcription factors, generating ADP and a phosphorylated tyrosine substrate. The generic reaction can be summarized as:  
   ATP + [protein]-Tyr → ADP + [protein]-Tyr-phosphate + H⁺ (ungureanu2005posttranslationalmodificationsin pages 11-14, niranjan2014functionalcharacterizationof pages 14-19).
3. Cofactor Requirements – JAK2 requires divalent cations to facilitate its catalytic activity. The enzyme relies primarily on Mg²⁺ as a cofactor for proper ATP binding and transfer of the phosphate group to its substrates. In addition, certain biochemical assays and studies of the pseudokinase domain’s autophosphorylation have indicated that Mn²⁺ can strongly enhance catalytic activity in specific contexts (kotyla2021thromboembolicadversedrug pages 2-4, niranjan2014functionalcharacterizationof pages 123-123).
4. Substrate Specificity – Substrate recognition by JAK2 is largely determined by its ability to interact with tyrosine residues present on the cytoplasmic domains of various cytokine receptors. JAK2 phosphorylates specific receptor tyrosines, thereby creating docking sites for downstream signaling proteins such as STAT family members. Once recruited, STAT proteins are themselves phosphorylated on specific tyrosine sites, which promotes their dimerization and nuclear translocation. Although no single consensus sequence has been universally defined, the substrate specificity is conferred by docking interactions with receptor motifs and by the unique structural context provided by each receptor’s cytoplasmic tail (hubbard2018mechanisticinsightsinto pages 1-2, jatiani2010jakstatpathwaysin pages 1-2, niranjan2014functionalcharacterizationof pages 10-14).
5. Structure – JAK2 is organized into multiple distinct domains that orchestrate its enzymatic and regulatory functions. The N-terminal portion contains a FERM domain responsible for binding to cytokine receptors, which facilitates membrane localization. Immediately adjacent is an SH2-like (SH2L) domain that contributes to protein–protein interactions involved in signal transduction. The central region comprises the pseudokinase domain (JH2), which is structurally similar to classical kinases yet exhibits limited catalytic activity; this domain plays a pivotal role in autoinhibition by interacting with the active kinase domain (JH1). The C-terminal JH1 domain contains the canonical bilobed structure with an activation loop that requires phosphorylation (e.g., tyrosine 1007) to achieve full catalytic activity. Structural models and crystallographic studies have revealed that the JH2 domain, despite being termed a pseudokinase, binds ATP (albeit with lower affinity) and mediates autophosphorylation on key regulatory sites (Ser523 and Tyr570), which in turn modulate the activity of the JH1 domain (hubbard2018mechanisticinsightsinto pages 1-2, lindauer2001predictionofthe pages 3-3, niranjan2014functionalcharacterizationof pages 127-128). Additional structural determinants such as the hydrophobic spine and the C-helix in the kinase domain are critical for maintaining the active conformation, while the juxtaposition of the JH2 and JH1 domains provides a mechanism for intramolecular regulation (wilks2008thejakkinases pages 5-6, niranjan2014functionalcharacterizationof pages 137-141).
6. Regulation – The activity of JAK2 is tightly controlled by multiple regulatory mechanisms that involve both inter- and intramolecular interactions. The pseudokinase domain (JH2) plays an essential role in maintaining low basal activity by inhibiting the kinase domain (JH1) under resting conditions. Autophosphorylation events occur on both domains; phosphorylation of key residues such as Y1007 within the JH1 activation loop is necessary for full activation, whereas autophosphorylation on Ser523 and Tyr570 within the JH2 domain serves a negative regulatory function, reinforcing the autoinhibitory conformation (hubbard2018mechanisticinsightsinto pages 3-5, niranjan2014functionalcharacterizationof pages 123-123, niranjan2014functionalcharacterizationof pages 126-127). Mutations in the JH2 domain, most notably the V617F substitution, disrupt these regulatory interactions by abrogating the inhibitory effects, resulting in constitutive kinase activation and unregulated downstream signaling (hubbard2018mechanisticinsightsinto pages 1-2, jatiani2010jakstatpathwaysin pages 8-9, niranjan2014functionalcharacterizationof pages 115-117). Additionally, binding of JAK2 to receptor cytoplasmic tails through the FERM domain and the involvement of the SH2-like domain further contribute to its regulated activation in response to cytokine stimulation (wilks2008thejakkinases pages 6-8, niranjan2014functionalcharacterizationof pages 114-119).
7. Function – JAK2 functions as a critical non-receptor tyrosine kinase in the transmission of signals from a diverse array of cell-surface receptors. In the cytoplasm, JAK2 associates with type I and type II cytokine receptors—including those for growth hormone, prolactin, leptin, erythropoietin, and thrombopoietin—and mediates phosphorylation of receptor tyrosine residues upon ligand activation. This creates binding sites for STAT transcription factors, which are subsequently phosphorylated by JAK2. Phosphorylated STATs dimerize and translocate into the nucleus, where they drive gene transcription programs essential for processes such as hematopoiesis, immune regulation, cell growth, and differentiation (hubbard2018mechanisticinsightsinto pages 1-2, jatiani2010jakstatpathwaysin pages 1-2, niranjan2014functionalcharacterizationof pages 10-14). In addition to its canonical signaling role, JAK2 also functions in the nucleus where it phosphorylates histone H3 on tyrosine 41, thereby influencing chromatin organization and gene expression. Other cellular processes regulated by JAK2 include cell cycle progression through phosphorylation of targets like CDKN1B, modulation of ion channel activity via up-regulation of potassium channels such as KCNA3, and mechanisms of reciprocal phosphorylation with other kinases such as TEC, which together impact the transcription of immediate early genes like FOS (hubbard2018mechanisticinsightsinto pages 5-6, niranjan2014functionalcharacterizationof pages 141-144).
8. Other Comments – JAK2 is of particular clinical significance due to its implication in myeloproliferative neoplasms and other hematologic disorders. The activating V617F mutation, located in the pseudokinase domain, is found in over 90% of polycythemia vera cases and in approximately 50% of cases of essential thrombocythemia and primary myelofibrosis. This mutation disrupts the normal autoinhibitory function of the JH2 domain and leads to constitutive activation of the kinase, making it a prime target for therapeutic inhibition. Several small-molecule inhibitors targeting the ATP-binding site of the JH1 domain have been developed, including ruxolitinib and TG101348, among others, and are in various phases of clinical evaluation for their efficacy in modulating aberrant JAK2 signaling (jatiani2010jakstatpathwaysin pages 9-11, kotyla2021thromboembolicadversedrug pages 2-4, niranjan2014functionalcharacterizationof pages 117-119). In addition to these inhibitors, ongoing studies are aimed at developing agents that can selectively target mutant forms of JAK2 to minimize adverse effects on normal hematopoiesis (wilks2008thejakkinases pages 6-8, niranjan2014functionalcharacterizationof pages 152-156).
9. References
10. hubbard2018mechanisticinsightsinto. Stevan R. Hubbard. “Mechanistic insights into regulation of jak2 tyrosine kinase.” Frontiers in Endocrinology, Jan 2018. DOI:10.3389/fendo.2017.00361.
11. jatiani2010jakstatpathwaysin. S. S. Jatiani, S. J. Baker, L. R. Silverman, and E. P. Reddy. “Jak/stat pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.” Genes & Cancer, Oct 2010. DOI:10.1177/1947601910397187.
12. lindauer2001predictionofthe. Klaus Lindauer, Thomas Loerting, Klaus R. Liedl, and Romano T. Kroemer. “Prediction of the structure of human janus kinase 2 (jak2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.” Protein Engineering, Design and Selection, Jan 2001. DOI:10.1093/protein/14.1.27.
13. murphy2014arobustmethodology. James M. Murphy et al. “A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties.” The Biochemical Journal, Jan 2014. DOI:10.1042/bj20131174.
14. niranjan2014functionalcharacterizationof. Y. Niranjan. “Functional Characterization of the Kinase and Pseudokinase Domains in the Janus Tyrosine Kinase (JAK) 2.” Unknown journal, 2014.
15. ungureanu2005posttranslationalmodificationsin. D. Ungureanu. “Post-translational modifications in regulation of jak-stat pathway.” Unknown journal, 2005.
16. wilks2008thejakkinases. Andrew F. Wilks. “The jak kinases: not just another kinase drug discovery target.” Seminars in Cell & Developmental Biology, Aug 2008. DOI:10.1016/j.semcdb.2008.07.020.
17. kotyla2021thromboembolicadversedrug. Przemysław J. Kotyla, Małgorzata Engelmann, Joanna Giemza-Stokłosa, Bartosz Wnuk, and Md Asiful Islam. “Thromboembolic adverse drug reactions in janus kinase (jak) inhibitors: does the inhibitor specificity play a role?” International Journal of Molecular Sciences, Feb 2021. DOI:10.3390/ijms22052449.

References

1. (hubbard2018mechanisticinsightsinto pages 1-2): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
2. (hubbard2018mechanisticinsightsinto pages 3-5): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
3. (jatiani2010jakstatpathwaysin pages 1-2): S. S. Jatiani, S. J. Baker, L. R. Silverman, and E. P. Reddy. Jak/stat pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes & Cancer, 1:979-993, Oct 2010. URL: https://doi.org/10.1177/1947601910397187, doi:10.1177/1947601910397187. This article has 333 citations.
4. (jatiani2010jakstatpathwaysin pages 2-3): S. S. Jatiani, S. J. Baker, L. R. Silverman, and E. P. Reddy. Jak/stat pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes & Cancer, 1:979-993, Oct 2010. URL: https://doi.org/10.1177/1947601910397187, doi:10.1177/1947601910397187. This article has 333 citations.
5. (jatiani2010jakstatpathwaysin pages 8-9): S. S. Jatiani, S. J. Baker, L. R. Silverman, and E. P. Reddy. Jak/stat pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes & Cancer, 1:979-993, Oct 2010. URL: https://doi.org/10.1177/1947601910397187, doi:10.1177/1947601910397187. This article has 333 citations.
6. (lindauer2001predictionofthe pages 1-2): Klaus Lindauer, Thomas Loerting, Klaus R. Liedl, and Romano T. Kroemer. Prediction of the structure of human janus kinase 2 (jak2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Engineering, Design and Selection, 14:27-37, Jan 2001. URL: https://doi.org/10.1093/protein/14.1.27, doi:10.1093/protein/14.1.27. This article has 253 citations.
7. (lindauer2001predictionofthe pages 3-3): Klaus Lindauer, Thomas Loerting, Klaus R. Liedl, and Romano T. Kroemer. Prediction of the structure of human janus kinase 2 (jak2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Engineering, Design and Selection, 14:27-37, Jan 2001. URL: https://doi.org/10.1093/protein/14.1.27, doi:10.1093/protein/14.1.27. This article has 253 citations.
8. (niranjan2014functionalcharacterizationof pages 10-14): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
9. (niranjan2014functionalcharacterizationof pages 115-117): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
10. (niranjan2014functionalcharacterizationof pages 126-127): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
11. (niranjan2014functionalcharacterizationof pages 127-128): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
12. (niranjan2014functionalcharacterizationof pages 137-141): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
13. (niranjan2014functionalcharacterizationof pages 152-156): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
14. (ungureanu2005posttranslationalmodificationsin pages 11-14): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
15. (wilks2008thejakkinases pages 5-6): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
16. (wilks2008thejakkinases pages 6-8): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
17. (hubbard2018mechanisticinsightsinto pages 5-6): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
18. (jatiani2010jakstatpathwaysin pages 9-11): S. S. Jatiani, S. J. Baker, L. R. Silverman, and E. P. Reddy. Jak/stat pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes & Cancer, 1:979-993, Oct 2010. URL: https://doi.org/10.1177/1947601910397187, doi:10.1177/1947601910397187. This article has 333 citations.
19. (kotyla2021thromboembolicadversedrug pages 2-4): Przemysław J. Kotyla, Małgorzata Engelmann, Joanna Giemza-Stokłosa, Bartosz Wnuk, and Md Asiful Islam. Thromboembolic adverse drug reactions in janus kinase (jak) inhibitors: does the inhibitor specificity play a role? International Journal of Molecular Sciences, 22:2449, Feb 2021. URL: https://doi.org/10.3390/ijms22052449, doi:10.3390/ijms22052449. This article has 58 citations and is from a peer-reviewed journal.
20. (niranjan2014functionalcharacterizationof pages 117-119): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
21. (niranjan2014functionalcharacterizationof pages 123-123): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
22. (niranjan2014functionalcharacterizationof pages 14-19): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.
23. (niranjan2014functionalcharacterizationof pages 141-144): Y Niranjan. Functional characterization of the kinase and pseudokinase domains in the janus tyrosine kinase (jak) 2. Unknown journal, 2014.